Niranjan Manoharan, MD
Retina Specialist · Aurora, CONPI 1598182453
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,345 of the $9,015 with a category attached, or 70.4%. Genentech, Inc. accounts for 78.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $7,115 and has fallen 99.3% since, to $52 in 2025.
Across 24 payments — averaging $375.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$7K
- Regeneron$806
- Carl Zeiss Meditec USA, Inc.$274
- Novartis$242
- Dutch Ophthalmic, USA$218
- Regeneron Healthcare Solutions, Inc.$125
- plus $254 from 4 others
Across 21 payments — averaging $14,320 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$224K
- Astellas Pharma Global Development$49K
- Regeneron$21K
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Consulting fees$6,34570%
- Travel & lodging$1,38015%
- Food & beverage$1,29014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 6 | $7,096 |
| Regeneron | 2 | $806 |
| Carl Zeiss Meditec USA, Inc. | 2 | $274 |
| Novartis | 2 | $242 |
| Dutch Ophthalmic, USA | 3 | $218 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| AbbVie | 1 | $125 |
| Genentech USA, Inc. | 5 | $98 |
| Thea Pharma Inc. | 1 | $19 |
| Akorn Operating Company LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$7,052
- ARTEVO 800$274
- EVA, combined machine$172
- TISSUEBLUE$172
- EYLEA$125
- OZURDEX$125
How this compares
$9,015 in reported general payments places this provider in the 65th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 93 | $3,724 |
| Brimonidine Tartrate | 45 | $1,018 |
| Latanoprost | 65 | $670 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $636 |
| MoxifloxacinMoxifloxacin Hcl | 26 | $465 |
| Ketorolac Tromethamine | 13 | $292 |
| Dorzolamide Hcl | 11 | $158 |
| Timolol Maleate | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Aurora
- Talisa ForestAurora$84K
- Lynn HassmanAurora$16K
- Zachary KoretzAurora$14K
- Ross ChodAurora$10K
- Amit ReddyAurora$4K
- Rachel ChenAurora$4K
- Naresh MandavaAurora$3K
- Frank SiringoAurora$3K
- Abraham HangAurora$2K
- Sean RodriguezAurora$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.